Virtual Press Conference: FDA Clears AGT to Begin Phase 1 Clinical Trial of HIV Cure Program

Learn about AGT's HIV Cure Program in 1-Hour

Date: Thursday August 13, 1pm EST
Live Online | Media Only

What Will I Learn?

AGT is excited to announce its clearance by the FDA to begin a Phase I Trial for an HIV cure. Sign-up for this virtual press conference to learn the details of its program from AGT's Leadership.

  • world-cog-icon

    The theory and history behind the therapy - AGT103-T autologous cell therapy

  • document-pencil-icon

    What is know so far - Pre-clinical results and peer reviewed publications

  • arrow-up-icon

    Clinical and patient details - Clinical sites, enrollment plan, and timelines

What Is It For?

Reporters and media.

The event has passed but here is a recording of the virtual press conference.

AGT announces that it was cleared for FDA phase 1 clinical trials for AGT103-T, a potential HIV gene therapy cure

If you are interested in interviewing members of the company please contact us and we will reach out to you right away.

Meet the Speakers

Jeff Galvin

Chief Executive Officer

C. David Pauza, Ph.D.

Chief Science Officer